Intracranial aneurysms may represent a localized manifestation of premature vascular aging, with senescent endothelial and smooth muscle cells secreting a senescence-associated secretory phenotype (SASP) — a cocktail of pro-inflammatory cytokines, matrix-degrading enzymes (including MMPs), and oxidative stress mediators — that progressively degrades the extracellular matrix, recruits immune cells, and structurally weakens the aneurysm wall toward rupture.
This review arrives at a moment when the senescence field is rapidly transitioning from bench to bedside. The mechanistic framing here is significant: it recontextualizes intracranial aneurysms not merely as hemodynamic accidents but as biological endpoints of accelerated vascular aging — a shift with real clinical implications. If SASP-driven wall degeneration is causal rather than correlational, then senolytics (such as dasatinib-quercetin combinations, already in early human trials for other conditions) and senomorphics (agents that suppress SASP without clearing senescent cells) could theoretically stabilize aneurysms non-invasively — a major unmet need given that many small aneurysms are currently managed by watchful waiting.
Critically, this is a narrative review, not primary data, so no new causal evidence is introduced. The authors themselves acknowledge inconsistent associations between chronological age and rupture risk across natural-history cohorts, signaling that biological age, not calendar age, is the operative variable. For adults over 50 with known vascular risk factors, this framework strengthens the rationale for aggressive inflammaging management — though aneurysm-specific senolytic trials remain absent. Incremental but directionally important.
